GRI Bio NASDAQ GRI Bolsters Patent Portfolio

LA JOLLA, CA, June 27, 2023 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today provided an update to the progress of…Read More